C&G Editor in Chief, Erin Harris
-
Akamis Bio Takes On Advanced Solid Tumors
8/23/2023
Akamis Bio’s CEO, Dr. Howard Davis, explains the company's T-SIGn platform, the NG-350A trial, and how T-SIGn may impact CAR-T for solid tumors.
-
Understanding Donor Characteristics to Improve Allogeneic Cell Therapy Outcomes
8/7/2023
Efficiencies in donor selection reduce uncertainties about human leukocyte antigen (HLA) and improve patient outcomes.
-
Automation’s Role In Cell Therapy Manufacturing
7/31/2023
The need for standardization and automation are critical drivers of innovation in cell therapy manufacturing. Implementation of an automated workflow minimizes open processes and manual touchpoints, increases reproducibility, and improves traceability. This has the potential to reduce manufacturing failures and lower the cost of goods sold, thereby facilitating increased patient access.
-
Excision BioTherapeutics & Guide RNA
7/27/2023
Excision’s CEO Daniel Dornbusch to dig into its CRISPR-based therapy, EBT-101, as well as Guide RNA (gRNA) and why it is critical to EBT-101’s success.
-
Caribou Biosciences’ Co-Founder Talks The Future of Genome Editing
7/12/2023
Caribou Biosciences' Rachel Haurwitz, Ph.D. discusses Pfizer's $25 million equity investment in the company as well as its Cas12a chRDNA genome editing technology.
-
What A Week In CGT: Approvals And Advancements
6/29/2023
The cell and gene therapy sector has had quite a week. From FDA approvals to groundbreaking advancements, the cell and gene therapy space has had good news to share. Here’s what’s gone on in just the last week alone.
-
Decibel Therapeutics’ Gene Therapy Strategies To Restore Hearing And Balance
6/28/2023
Decibel Therapeutics is a Boston-based, clinical-stage biotech dedicated to discovering and developing transformative new medicines for hearing and balance disorders. I caught up with Decibel’s CEO and President, Laurence Reid, Ph.D. to learn more about gene therapy as a modality for the ear, the state of the clinical trial, and more.
-
The Outlook For Gene Editing In The U.S.
6/8/2023
Gene editing has evolved over the past several years, and 2023 is positioned be a truly pivotal year. To get a true understanding of the current and near-term outlook for gene editing, I caught up with Mike Lehmicke, Vice President, Science and Industry Affairs, Alliance for Regenerative Medicine (ARM).
-
Inside The ISCT Global Regulators Summit 2023
5/30/2023
The ISCT Global Regulators Summit occurred on May 30, 2023. Immediately following the Summit, I attended a post-event press conference to learn the key highlights of the proceedings. Here's what I learned.
-
The Latest On Cell & Gene Live And Cell & Gene: The Podcast
5/18/2023
April and May have been busy months for Cell & Gene: The Podcast and Cell & Gene Live. In case you missed it, here’s a look at just some of what we’ve covered including computational biology’s impact on gene therapy, the future of exosome science, and best practices for in-house CGT manufacturing.